NEAT Trial: Effects of Epirubicin on Breast Cancer
Author Information
Author(s): Earl H M, Hiller L, Dunn J A, Bathers S, Harvey P, Stanley A, Grieve R J, Agrawal R K, Fernando I N, Brunt A M, McAdam K, O'Reilly S, Rea D W, Spooner D, Poole C J
Primary Institution: University of Cambridge
Hypothesis
Does the anthracycline-based regimen ECMF improve relapse-free survival and overall survival compared to classical CMF in early breast cancer?
Conclusion
The NEAT trial found that ECMF is significantly more effective than CMF with no serious long-term toxicity or detriment to quality of life.
Supporting Evidence
- ECMF showed a 28% improvement in relapse-free survival compared to CMF.
- Patients receiving ECMF had lower common toxicity criteria scores.
- On-treatment deaths were more common with CMF than ECMF.
- Optimal course-delivered dose intensity was more frequently achieved in ECMF patients.
Takeaway
This study shows that a specific cancer treatment (ECMF) works better than an older treatment (CMF) without causing serious side effects.
Methodology
A large, randomised, phase III trial comparing ECMF with CMF in women with early-stage breast cancer.
Potential Biases
Potential bias due to the study being conducted in a limited number of centers and the reliance on self-reported toxicity.
Limitations
The study may not fully represent all patient demographics as it was conducted in specific UK centers.
Participant Demographics
Women with early-stage breast cancer, recruited from 65 UK centers.
Statistical Information
P-Value
P=0.0002
Confidence Interval
IQR 87–101%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website